Life Summary
Ahn Mi-chung is chairman of Bukwang Pharm. She also serves as chairman of the board of Bukwang Pharm.

She is focusing on selecting and concentrating Bukwang Pharm's research and development (R&D) assets, while accelerating clinical development of its key new-drug pipelines and the spin-off of its RNA business.

She was born on November 10, 1961.

She graduated from Yonsei University with a degree in biochemistry. She earned a master's degree in microbiology from Illinois State University in the United States and a doctoral degree in immunology from Rush University in Chicago. She later earned a master's degree in law from Chungnam National University.

She worked as a researcher at Illinois State University, the Rush University Cancer Center, the Korea Basic Science Institute and the Korea Research Institute of Bioscience and Biotechnology.

She entered the Ministry of Trade and Industry through a special appointment and worked as an administrative officer in its Energy Management Division and later in the Chemical and Biological Industries Division of the Ministry of Commerce, Industry and Energy. She served as a technology development planning evaluation committee member at the Korea Institute of Industrial Technology Evaluation and Planning, an examiner in the Genetic Engineering Examination Division of Examination Bureau 3 at the Korean Intellectual Property Office, and an appeal research officer at the Intellectual Property Tribunal.

She served as an outside director of Genexine and Medipost and was appointed CEO of SL Vigen in 2022. She became the first woman to serve as chairman of the board of OCI Holdings.

In 2025, she was appointed chairman and chairman of the board of Bukwang Pharm, whose largest shareholder is OCI Holdings.

She served as an adjunct professor at Pai Chai University and Yonsei University and is an advisory patent attorney at Eroom Patent Law Firm, now Jipyong.

#AhnMiChung #BukwangPharm #OCIHoldings #Biopharma #PatentAttorney #ResearchAndDevelopment #DrugDevelopment #RNA #BoardLeadership #OpenInnovation